Apellis Pharmaceuticals, Inc

(NASDAQ:APLS)

Latest On Apellis Pharmaceuticals, Inc (APLS):

Date/Time Type Description Signal Details
2023-05-25 17:48 ESTNewsApellis and Sobi to drop ALS candidate on Phase 2 setbackN/A
2023-05-18 17:01 ESTNewsApellis Pharmaceuticals: Biotech's Rising Star In C3 Inhibition SpaceN/A
2023-05-06 12:27 ESTNewsApellis Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call PresentationN/A
2023-05-06 12:27 ESTNewsApellis Pharmaceuticals, Inc. (APLS) Q1 2023 Earnings Call TranscriptN/A
2023-05-04 22:14 ESTNewsApellis Pharmaceuticals: Maintain 'Buy' Following Astellas' $5.9 Billion Acquisition Of Iveric BioN/A
2023-05-04 22:14 ESTNewsApellis Pharmaceuticals GAAP EPS of -$1.56 misses by $0.10, revenue of $44.84M beats by $18.74MN/A
2023-05-03 20:58 ESTNewsApellis Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-05-01 19:14 ESTNewsApellis weakness on Iveric Bio takeout is buying opportunity - analystN/A
2023-05-01 06:55 ESTNewsApellis Pharmaceuticals (APLS) Presents at the Association for Research in Vision and Ophthalmology Annual Meeting - SlideshowN/A
2023-04-03 17:26 ESTNewsApellis Pharmaceuticals may be worth $90-$100 a share in sale - analystN/A
2023-04-02 23:22 ESTNewsApellis Pharmaceuticals sees takeover interest from large pharma - BloombergN/A
2023-03-24 22:48 ESTNewsApellis Pharmaceuticals Is Poised For Dominance In Geographic Atrophy MarketN/A
2023-03-16 14:19 ESTNewsApellis Pharmaceuticals' Empaveli sNDA action date extended by FDAN/A
2023-02-23 11:44 ESTNewsApellis Pharmaceuticals prices $350M in stock offeringN/A
2023-02-22 09:58 ESTNewsApellis Pharmaceuticals to raise $300M in stock and warrants offeringN/A
2023-02-21 21:29 ESTNewsApellis Pharmaceuticals GAAP EPS of -$1.50 beats by $0.06, revenue of $22.66M misses by $1.86MN/A
2023-02-18 02:43 ESTNewsApellis wins FDA nod for eye disorder therapyN/A
2023-01-27 18:43 ESTNewsApellis: Empaveli Ought To Win Approval For Eye Disease In February - The Future Looks BrightN/A
2023-01-21 14:26 ESTNewsStocks To Watch: Earnings Heat Up, Healthcare Catalysts And M&A WildcardsN/A
2023-01-05 20:02 ESTNewsApellis appoints Baumal as Chief Medical OfficerN/A
2023-01-04 02:30 ESTNewsApellis, Arvinas lower as Wells Fargo downgrades in 2023 biotech previewN/A
2022-12-15 23:44 ESTNewsApellis Pharmaceuticals: Approval Is Baked Into ValuationN/A
2022-11-18 10:24 ESTNewsApellis surges 17% as FDA accepts to review new data in filing for eye disorder drugN/A
2022-11-11 06:07 ESTNewsApellis, IVERIC bio cut to Hold at Jefferies; says Street overestimates GA marketN/A
2022-11-08 08:01 ESTNewsApellis Pharmaceuticals GAAP EPS of -$1.75 misses by $0.29, revenue of $22.05M beats by $0.46MN/A
2022-11-08 08:00 ESTNewsApellis Pharmaceuticals, Inc. (APLS) Q3 2022 Earnings Call TranscriptN/A
2022-11-05 08:22 ESTNewsApellis Pharmaceuticals Q3 2022 Earnings PreviewN/A
2022-11-03 23:08 ESTNewsApellis sinks 20% as FDA review period for eye disease drug extendsN/A
2022-10-16 23:00 ESTNewsCiti lists four more value-creating events in biotech for this yearN/A
2022-09-29 06:33 ESTNewsApellis Pharmaceuticals: Trying To Develop A Blockbuster FranchiseN/A
2022-09-08 07:22 ESTNewsApellis gains as FDA says AdCom unnecessary for eye disease candidateN/A
2022-08-24 16:51 ESTNewsApellis stock dips amid 2-year data of pegcetacoplan for eye disorderN/A
2022-08-09 18:37 ESTNewsApellis Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-09 18:37 ESTNewsApellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-08 18:56 ESTNewsApellis Pharmaceuticals GAAP EPS of -$1.46 misses by $0.09, revenue of $16.32M misses by $0.63MN/A
2022-08-06 06:05 ESTNewsApellis Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-07-27 15:50 ESTNewsApellis to exchange $75.6M in convertible senior notes for common stockN/A
2022-07-20 18:36 ESTNewsApellis Pharmaceuticals: The Meaning Of Priority Review For Pegcetacoplan For Geographic AtrophyN/A
2022-07-20 03:57 ESTNewsWainwright sees blockbuster potential for Apellis eye degeneration therapy; shares up 22%N/A
2022-07-19 13:21 ESTNewsApellis stock soars 24% as FDA grants priority review to pegcetacoplan for eye disorderN/A
2022-07-19 13:19 ESTNewsH.C. Wainwright sees blockbuster potential for Apellis' treatment in eye degenerationN/A
2022-06-25 15:25 ESTNewsApellis: Mixed Data, But Definitely Approvable In GAN/A
2022-06-13 19:55 ESTNewsHot Stocks: APLS & SKIL both gain, TSLA declined despite upgrade, and VLTA plungedN/A
2022-06-10 11:34 ESTNewsApellis/Sobi Empaveli shows benefit in rare blood disorder patients in new analysesN/A
2022-06-01 11:05 ESTNewsApellis files for FDA approval of pegcetacoplan to treat eye disorderN/A
2022-05-06 19:17 ESTNewsApellis Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-06 19:15 ESTNewsApellis Pharmaceuticals (APLS) Investor Presentation - SlideshowN/A
2022-05-04 22:43 ESTNewsApellis Pharmaceuticals GAAP EPS of -$1.42 misses by $0.12, revenue of $12.1M misses by $0.52MN/A
2022-05-04 22:42 ESTNewsApellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-04 03:15 ESTNewsApellis Pharmaceuticals Q1 2022 Earnings PreviewN/A

About Apellis Pharmaceuticals, Inc (APLS):

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

See Advanced Chart

General

  • Name Apellis Pharmaceuticals, Inc
  • Symbol APLS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 374
  • Fiscal Year EndDecember
  • IPO Date2017-11-09
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.apellis.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 13.99
  • Price/Book (Most Recent Quarter) 18.33
  • Enterprise Value Revenue 12.97
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$6.46
  • Next Year EPS Estimate -$5.31
  • Next Quarter EPS Estimate -$1.60
  • Profit Margin -138%
  • Operating Margin -85%
  • Return on Assets -20%
  • Return on Equity -289%
  • Revenue 250.65 million
  • Earnings Per Share -$3.32
  • Revenue Per Share $3.34
  • Gross Profit -74325000
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 3.54 billion
  • Analyst Target Price $64.14
  • Book Value Per Share $2.69
View More

Share Statistics

  • Shares Outstanding 80.38 million
  • Shares Float 59.7 million
  • % Held by Insiders 2117%
  • % Held by Institutions 82.85%
  • Shares Short 8.11 million
  • Shares Short Prior Month 7.75 million
  • Short Ratio 13.44
  • Short % of Float 15%
  • Short % of Shares Outstanding 10%
View More

Technicals

  • Beta 1.52
  • 52 Week High $58.47
  • 52 Week Low $21.84
  • 50 Day Moving Average 46.47
  • 200 Day Moving Average 42.62
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Apellis Pharmaceuticals, Inc (APLS) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Apellis Pharmaceuticals, Inc (APLS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-25$N/A$0.93-$0.45304.58%
2020-09-302020-11-02$646000-$1.79-$1.58-13.31%
2020-06-302020-07-30$N/A-$1.57-$1.34-17.56%
2020-03-312020-04-29$N/A-$2.29-$1.39-64.72%
2019-12-312020-02-27$N/A-$1.77-$1.14-55%
2019-09-302019-11-05$N/A-$1.10-$1.03-6.44%
2019-06-302019-07-31$N/A-$1.12-$0.78-44.39%
2019-03-312019-05-07$N/A-$0.87-$0.68-27.49%
2018-12-312019-02-26$N/A-$0.65-$0.707.58%
2018-09-302018-11-13$N/A-$0.64-$0.697.02%
2018-06-302018-07-31$N/A-$0.61-$0.42-45.86%
2018-03-312018-04-30$N/A-$0.43-$0.27-57.28%
2017-12-312018-03-19$N/A-$0.61-$0.27-129.32%
2017-09-302017-12-20$N/A-$0.23-$0.242.75%

Apellis Pharmaceuticals, Inc (APLS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Apellis Pharmaceuticals, Inc (APLS) Chart:

Apellis Pharmaceuticals, Inc (APLS) News:

Below you will find a list of latest news for Apellis Pharmaceuticals, Inc (APLS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Apellis Pharmaceuticals, Inc (APLS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-06-20110CALL0 2181.31TRUE00
2025-06-20120CALL0 087.79TRUE00
2025-06-20130CALL0 3207.51TRUE00
2025-06-20140CALL0 3112.49TRUE00
2025-06-20153.75CALL0 292.29TRUE00
2025-06-20163.35CALL0 172.94TRUE00
2025-06-20172.49CALL0 7961.39TRUE00
2025-06-20181.93CALL4 43562.04TRUE1.930
2025-06-20190.81CALL0 34263.38TRUE00
2025-06-20200.55CALL0 79762.94FALSE00
2025-06-20210.35CALL0 11961.9FALSE00
2025-06-20220.19CALL10 41665.46FALSE-0.04-0.17
2025-06-20230.09CALL0 42970.73FALSE00
2025-06-20240.1CALL0 1113.88FALSE00
2025-06-20250.14CALL0 43101.95FALSE00
2025-06-20260CALL0 0112.8FALSE00
2025-06-20270CALL0 0150.41FALSE00
2025-06-20280CALL0 0161.05FALSE00
2025-06-20300CALL0 0107.05FALSE00
2025-06-20350CALL0 0221.84FALSE00
2025-06-20110PUT0 0248.26FALSE00
2025-06-20120PUT0 0217.41FALSE00
2025-06-20130.05PUT0 9188.76FALSE00
2025-06-20140.05PUT0 11397.83FALSE00
2025-06-20150.1PUT0 206107.35FALSE00
2025-06-20160.18PUT0 10073.8FALSE00
2025-06-20170.15PUT8 28962.18FALSE0.150
2025-06-20180.35PUT4 17460.49FALSE-0.15-0.3
2025-06-20190.83PUT0 6265.67FALSE00
2025-06-20201.19PUT1 9253.85TRUE-0.32-0.21
2025-06-20212.4PUT0 168.8TRUE00
2025-06-20223.55PUT0 064.43TRUE00
2025-06-20233.85PUT0 175.12TRUE00
2025-06-20240PUT0 0127.17TRUE00
2025-06-20250PUT0 077.96TRUE00
2025-06-20260PUT0 0143.12TRUE00
2025-06-20270PUT0 0165.67TRUE00
2025-06-20280PUT0 0104.54TRUE00
2025-06-20300PUT0 0208.45TRUE00
2025-06-20350PUT0 0213.18TRUE00
2025-07-18110CALL0 0105.42TRUE00
2025-07-18127.35CALL0 080.72TRUE00
2025-07-18136.45CALL0 195.75TRUE00
2025-07-18145.55CALL0 076.4TRUE00
2025-07-18154.05CALL0 5963.26TRUE00
2025-07-18163.35CALL0 4167.86TRUE00
2025-07-18172.69CALL0 1468.8TRUE00
2025-07-18182.55CALL3 34271.97TRUE0.090.04
2025-07-18192.1CALL41 62666.07TRUE0.350.2
2025-07-18201.5CALL31 43768.68FALSE0.050.03
2025-07-18211.19CALL0 4360.96FALSE00
2025-07-18220.85CALL0 3562.93FALSE00
2025-07-18230.28CALL0 1862.03FALSE00
2025-07-18240.45CALL0 4263.53FALSE00
2025-07-18250CALL0 2164.44FALSE00
2025-07-18260CALL0 3865.17FALSE00
2025-07-18270CALL0 2768.76FALSE00
2025-07-18280CALL0 2188.42FALSE00
2025-07-18290CALL0 4295.82FALSE00
2025-07-18300CALL0 52575.07FALSE00
2025-07-18310CALL0 2106.28FALSE00
2025-07-18320CALL0 62111.13FALSE00
2025-07-18330CALL0 20115.76FALSE00
2025-07-18340CALL0 1120.19FALSE00
2025-07-18350.3CALL0 137124.44FALSE00
2025-07-18360CALL0 2128.53FALSE00
2025-07-18370CALL0 2004132.45FALSE00
2025-07-18380CALL0 1136.23FALSE00
2025-07-18390CALL0 21139.88FALSE00
2025-07-18400CALL0 11143.41FALSE00
2025-07-18410CALL0 3146.81FALSE00
2025-07-18420CALL0 13150.11FALSE00
2025-07-18450CALL0 1159.42FALSE00
2025-07-18500CALL0 13173.26FALSE00
2025-07-18110PUT0 0140.39FALSE00
2025-07-18120.3PUT0 12123.02FALSE00
2025-07-18130PUT0 1106.89FALSE00
2025-07-18140PUT0 5573.35FALSE00
2025-07-18150.87PUT0 2260.99FALSE00
2025-07-18160.5PUT0 11369.66FALSE00
2025-07-18170.64PUT30 11463.78FALSE-0.11-0.15
2025-07-18180.9PUT2 31666.09FALSE-0.17-0.16
2025-07-18191.65PUT0 21064.67FALSE00
2025-07-18200PUT0 862.53TRUE00
2025-07-18212.5PUT0 200265.72TRUE00
2025-07-18223.55PUT0 464.82TRUE00
2025-07-18234.35PUT0 8267.83TRUE00
2025-07-18245.05PUT0 465.9TRUE00
2025-07-18255.95PUT0 13067.07TRUE00
2025-07-18260PUT0 377.32TRUE00
2025-07-18270PUT0 166.77TRUE00
2025-07-18280PUT0 2102.9TRUE00
2025-07-18290PUT0 1109.06TRUE00
2025-07-18300PUT0 0114.89TRUE00
2025-07-18310PUT0 5120.43TRUE00
2025-07-18320PUT0 0111.51TRUE00
2025-07-18330PUT0 0137.09TRUE00
2025-07-18340PUT0 091.44TRUE00
2025-07-18350PUT0 0140.27TRUE00
2025-07-18360PUT0 0137.56TRUE00
2025-07-18370PUT0 0124.24TRUE00
2025-07-18380PUT0 0115.5TRUE00
2025-07-18390PUT0 0109.44TRUE00
2025-07-18400PUT0 1153.58TRUE00
2025-07-18410PUT0 0164.83TRUE00
2025-07-18420PUT0 0160.84TRUE00
2025-07-18450PUT0 0145.63TRUE00
2025-07-18500PUT0 0208.44TRUE00
2025-10-17100CALL0 081.74TRUE00
2025-10-17118.91CALL30 3084.25TRUE8.910
2025-10-17120CALL0 060.89TRUE00
2025-10-17130CALL0 371.84TRUE00
2025-10-17145.9CALL0 472.87TRUE00
2025-10-17154.29CALL0 071.93TRUE00
2025-10-17160CALL0 069.67TRUE00
2025-10-17174.6CALL0 1270.18TRUE00
2025-10-17182.58CALL0 3979.94TRUE00
2025-10-17193.18CALL0 4568.54TRUE00
2025-10-17203CALL0 33868.89FALSE00
2025-10-17212.6CALL0 3466.62FALSE00
2025-10-17221.53CALL0 3867.22FALSE00
2025-10-17230CALL0 3968.07FALSE00
2025-10-17240.95CALL0 13766.47FALSE00
2025-10-17251.6CALL0 4165.77FALSE00
2025-10-17261.08CALL0 666.16FALSE00
2025-10-17270CALL0 1065.94FALSE00
2025-10-17280CALL0 3364.37FALSE00
2025-10-17290CALL0 356.11FALSE00
2025-10-17300.8CALL0 6065.17FALSE00
2025-10-17310CALL0 5858.26FALSE00
2025-10-17320CALL0 358.8FALSE00
2025-10-17330.25CALL0 2057.68FALSE00
2025-10-17340CALL0 060.04FALSE00
2025-10-17350CALL0 060.9FALSE00
2025-10-17360CALL0 561.54FALSE00
2025-10-17400CALL0 2683.58FALSE00
2025-10-17100PUT0 099.41FALSE00
2025-10-17110PUT0 071.07FALSE00
2025-10-17120.55PUT0 9666.85FALSE00
2025-10-17130PUT0 1761.98FALSE00
2025-10-17140PUT0 11373.61FALSE00
2025-10-17150PUT0 4672.99FALSE00
2025-10-17160PUT0 471.67FALSE00
2025-10-17170PUT0 1371.06FALSE00
2025-10-17182.62PUT0 270.43FALSE00
2025-10-17192.8PUT100 7467.58FALSE-0.1-0.03
2025-10-17200PUT0 3069.26TRUE00
2025-10-17210PUT0 1567.7TRUE00
2025-10-17224.73PUT0 5467.38TRUE00
2025-10-17230PUT0 266.14TRUE00
2025-10-17240PUT0 268.59TRUE00
2025-10-17250PUT0 6566.86TRUE00
2025-10-17260PUT0 466.71TRUE00
2025-10-17270PUT0 365.86TRUE00
2025-10-17280PUT0 067.09TRUE00
2025-10-17290PUT0 066.25TRUE00
2025-10-17300PUT0 066.4TRUE00
2025-10-17310PUT0 063.85TRUE00
2025-10-17320PUT0 055.12TRUE00
2025-10-17330PUT0 075.84TRUE00
2025-10-17340PUT0 084.03TRUE00
2025-10-17350PUT0 062.84TRUE00
2025-10-17360PUT0 069.43TRUE00
2025-10-17400PUT0 0125.1TRUE00
2026-01-16100CALL0 081.43TRUE00
2026-01-16110CALL0 077.08TRUE00
2026-01-16120CALL0 074.11TRUE00
2026-01-16130CALL0 869.16TRUE00
2026-01-16140CALL0 072.95TRUE00
2026-01-16150CALL0 3974.9TRUE00
2026-01-16160CALL0 170.47TRUE00
2026-01-16173.9CALL0 6070.63TRUE00
2026-01-16184.05CALL0 10870.02TRUE00
2026-01-16190CALL0 269.65TRUE00
2026-01-16203.9CALL0 1028569.53FALSE00
2026-01-16212.6CALL0 10168.83FALSE00
2026-01-1622.52.8CALL0 3666.01FALSE00
2026-01-16240CALL0 066.69FALSE00
2026-01-16252.23CALL0 17465.33FALSE00
2026-01-16260CALL0 064.39FALSE00
2026-01-16301.3CALL0 150664.98FALSE00
2026-01-16350CALL0 114663.46FALSE00
2026-01-16400.3CALL0 1062158.31FALSE00
2026-01-16450.3CALL1 33364.04FALSE0.30
2026-01-16500CALL0 34068.69FALSE00
2026-01-16550CALL0 39092.8FALSE00
2026-01-16600CALL0 107778.32FALSE00
2026-01-16650CALL0 402100.89FALSE00
2026-01-16700CALL0 35684.74FALSE00
2026-01-16750CALL0 139102.79FALSE00
2026-01-16800CALL0 19584.3FALSE00
2026-01-16850CALL0 653108.34FALSE00
2026-01-16900CALL0 84108.2FALSE00
2026-01-16950CALL0 24113.97FALSE00
2026-01-161000CALL0 27106.18FALSE00
2026-01-161050CALL0 96115.78FALSE00
2026-01-16100PUT0 1268.66FALSE00
2026-01-16110PUT0 064.19FALSE00
2026-01-16120PUT0 562.37FALSE00
2026-01-16130PUT0 10058.03FALSE00
2026-01-16140PUT0 072.98FALSE00
2026-01-16152.42PUT0 12771.5FALSE00
2026-01-16160PUT0 070.85FALSE00
2026-01-16170PUT0 169.93FALSE00
2026-01-16180PUT0 070.14FALSE00
2026-01-16193.7PUT0 269.19FALSE00
2026-01-16204.2PUT20 52167.65TRUE4.20
2026-01-16210PUT0 067.25TRUE00
2026-01-1622.50PUT0 966.43TRUE00
2026-01-16240PUT0 2566.14TRUE00
2026-01-16257.64PUT0 15765.35TRUE00
2026-01-16260PUT0 064.94TRUE00
2026-01-16300PUT0 123663.8TRUE00
2026-01-16350PUT0 83660.31TRUE00
2026-01-16400PUT0 162.15TRUE00
2026-01-16450PUT0 0101.25TRUE00
2026-01-16500PUT0 1281.28TRUE00
2026-01-16550PUT0 2387.96TRUE00
2026-01-16600PUT0 096.67TRUE00
2026-01-16650PUT0 337102.29TRUE00
2026-01-16700PUT0 1163100.43TRUE00
2026-01-16750PUT0 0116.96TRUE00
2026-01-16800PUT0 0123.6TRUE00
2026-01-16850PUT0 0143.7TRUE00
2026-01-16900PUT0 0160.06TRUE00
2026-01-16950PUT0 0164.07TRUE00
2026-01-161000PUT0 0163.18TRUE00
2026-01-161050PUT0 0159.09TRUE00
2027-01-1550CALL0 078.47TRUE00
2027-01-15109CALL0 553.18TRUE00
2027-01-15158.4CALL10 22666.3TRUE0.40.05
2027-01-15200CALL0 8660.99FALSE00
2027-01-15230CALL0 2859.68FALSE00
2027-01-15250CALL0 3557.89FALSE00
2027-01-15280CALL0 456.57FALSE00
2027-01-15302.3CALL0 13663.31FALSE00
2027-01-15332.52CALL0 449.52FALSE00
2027-01-15350CALL0 3255.51FALSE00
2027-01-15370CALL0 055.06FALSE00
2027-01-15401.72CALL0 4953.82FALSE00
2027-01-15420CALL0 273652.36FALSE00
2027-01-15450.85CALL0 3446.46FALSE00
2027-01-15470CALL0 047.22FALSE00
2027-01-15500CALL0 3647.58FALSE00
2027-01-15550CALL0 41048.2FALSE00
2027-01-1550PUT0 0174.95FALSE00
2027-01-15100PUT0 066.67FALSE00
2027-01-15153PUT0 32960.45FALSE00
2027-01-15205.59PUT0 25759.64TRUE00
2027-01-15230PUT0 259TRUE00
2027-01-15259.44PUT0 36258.35TRUE00
2027-01-15280PUT0 048.98TRUE00
2027-01-15300PUT0 156.22TRUE00
2027-01-153316.37PUT0 555.59TRUE00
2027-01-15350PUT0 355.23TRUE00
2027-01-15370PUT0 056.29TRUE00
2027-01-15400PUT0 069.92TRUE00
2027-01-15420PUT0 255.5TRUE00
2027-01-15450PUT0 077.87TRUE00
2027-01-15470PUT0 072.44TRUE00
2027-01-15500PUT0 092.13TRUE00
2027-01-15550PUT0 092.8TRUE00

Latest APLS Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST5$39.4
Jun 13, 2022 7:59 PM EST25$39.4
Jun 13, 2022 7:59 PM EST86$39.39
Jun 13, 2022 7:59 PM EST14$39.4
Jun 13, 2022 7:59 PM EST32$39.4

Apellis Pharmaceuticals, Inc (APLS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220021048/0001127602-20-021048-index.htm
2020-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1492422/000083423720004741/0000834237-20-004741-index.htm
2020-02-053/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320003295/0000899243-20-003295-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004260/0000899243-20-004260-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004262/0000899243-20-004262-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004264/0000899243-20-004264-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004268/0000899243-20-004268-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004275/0000899243-20-004275-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004281/0000899243-20-004281-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004288/0000899243-20-004288-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004299/0000899243-20-004299-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004303/0000899243-20-004303-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004312/0000899243-20-004312-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004314/0000899243-20-004314-index.htm
2020-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320008068/0000899243-20-008068-index.htm
2020-10-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320027595/0000899243-20-027595-index.htm
2020-10-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320027598/0000899243-20-027598-index.htm
2020-02-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1492422/000090221920000352/0000902219-20-000352-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1492422/000090266420001196/0000902664-20-001196-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1492422/000092963820000336/0000929638-20-000336-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220005685/0001127602-20-005685-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220006429/0001127602-20-006429-index.htm
2020-02-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220006654/0001127602-20-006654-index.htm
2020-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220011988/0001127602-20-011988-index.htm
2020-04-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220013334/0001127602-20-013334-index.htm
2020-04-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220013338/0001127602-20-013338-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220014098/0001127602-20-014098-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220014100/0001127602-20-014100-index.htm
2020-04-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220014554/0001127602-20-014554-index.htm
2020-05-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220016304/0001127602-20-016304-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220017178/0001127602-20-017178-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220017181/0001127602-20-017181-index.htm
2020-06-093Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220019258/0001127602-20-019258-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220019731/0001127602-20-019731-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220019733/0001127602-20-019733-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220019735/0001127602-20-019735-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220021048/0001127602-20-021048-index.htm
2020-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220021646/0001127602-20-021646-index.htm
2020-08-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220022885/0001127602-20-022885-index.htm
2020-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220023992/0001127602-20-023992-index.htm
2020-08-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220024043/0001127602-20-024043-index.htm
2020-09-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220024640/0001127602-20-024640-index.htm
2020-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220025183/0001127602-20-025183-index.htm
2020-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220026264/0001127602-20-026264-index.htm
2020-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220026748/0001127602-20-026748-index.htm
2020-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220026750/0001127602-20-026750-index.htm
2020-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220027098/0001127602-20-027098-index.htm
2020-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220027101/0001127602-20-027101-index.htm
2020-11-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220027991/0001127602-20-027991-index.htm
2020-02-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1492422/000119312520052855/0001193125-20-052855-index.htm
2020-02-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1492422/000119312520052867/0001193125-20-052867-index.htm
2020-04-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1492422/000119312520098977/0001193125-20-098977-index.htm
2020-04-22DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1492422/000119312520115068/0001193125-20-115068-index.htm
2020-04-22DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1492422/000119312520115084/0001193125-20-115084-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1492422/000119312520135621/0001193125-20-135621-index.htm
2020-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1492422/000119312520141579/0001193125-20-141579-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1492422/000119312520157384/0001193125-20-157384-index.htm
2020-10-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1492422/000119312520277496/0001193125-20-277496-index.htm
2010-05-19DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1492242/000149224210000001/0001492242-10-000001-index.htm
2020-02-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1492422/000156459020007350/0001564590-20-007350-index.htm
2020-04-2910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1492422/000156459020019689/0001564590-20-019689-index.htm
2020-07-3010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1492422/000156459020034763/0001564590-20-034763-index.htm
2020-11-0210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1492422/000156459020049423/0001564590-20-049423-index.htm
2020-08-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1492422/999999999720004458/9999999997-20-004458-index.htm

Apellis Pharmaceuticals, Inc (APLS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Apellis Pharmaceuticals, Inc (APLS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2117%
Institutional Ownership: 8285%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-02-13Pascal DeschateletsChief Operating OfficerSell55,398.0040.982,270,154.641,008,681.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220005685/0001127602-20-005685-index.htm
2020-02-18Cedric FrancoisChief Executive OfficerSell5,000.0040.67203,330.001,027,430.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006654/0001127602-20-006654-index.htm
2020-02-18Cedric FrancoisChief Executive OfficerSell30,637.0040.661,245,792.331,032,430.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006654/0001127602-20-006654-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell300.0023.867,158.001,053,067.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell3,212.0022.2871,556.941,053,367.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell15,065.0021.58325,087.641,056,579.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-02-19Cedric FrancoisChief Executive OfficerBuy30,637.002.1465,563.181,058,067.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006654/0001127602-20-006654-index.htm
2020-02-18Cedric FrancoisChief Executive OfficerBuy30,637.002.1465,563.181,063,067.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006654/0001127602-20-006654-index.htm
2020-02-13Pascal DeschateletsChief Operating OfficerBuy117,205.002.14250,818.701,064,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220005685/0001127602-20-005685-index.htm
2020-02-10Cedric FrancoisChief Executive OfficerBuy34,375.001,066,805.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004299/0000899243-20-004299-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell12,060.0020.69249,557.581,071,644.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-10-15Cedric FrancoisChief Executive OfficerSell5,000.0034.46172,300.001,083,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220027098/0001127602-20-027098-index.htm
2020-03-17Cedric FrancoisChief Executive OfficerBuy30,637.002.1465,563.181,083,704.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell700.0022.2915,600.201,083,704.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell2,192.0021.5747,279.251,084,404.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell2,108.0020.7343,694.621,086,596.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-09-15Cedric FrancoisChief Executive OfficerSell5,000.0030.96154,800.001,088,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220025183/0001127602-20-025183-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerBuy30,637.002.1465,563.181,088,704.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-08-20Cedric FrancoisChief Executive OfficerSell3,457.0030.00103,710.001,093,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220024043/0001127602-20-024043-index.htm
2020-08-18Cedric FrancoisChief Executive OfficerSell1,543.0030.0046,290.001,096,536.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220023992/0001127602-20-023992-index.htm
2020-07-15Cedric FrancoisChief Executive OfficerSell5,000.0032.12160,600.001,098,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220021646/0001127602-20-021646-index.htm
2020-06-15Cedric FrancoisChief Executive OfficerSell5,000.0030.21151,050.001,103,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220019731/0001127602-20-019731-index.htm
2020-05-15Cedric FrancoisChief Executive OfficerSell5,000.0029.92149,600.001,108,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220017181/0001127602-20-017181-index.htm
2020-04-15Cedric FrancoisChief Executive OfficerSell5,000.0029.77148,850.001,113,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220014100/0001127602-20-014100-index.htm
2020-02-10LUKAS SCHEIBLEROfficerBuy9,375.0012,310.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004314/0000899243-20-004314-index.htm
2020-10-07Victoria L. BrownProgram Team LeadBuy12,000.0018.98227,760.0015,607.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220026748/0001127602-20-026748-index.htm
2020-02-10Timothy Eugene SullivanChief Financial OfficerBuy11,688.0023,387.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004303/0000899243-20-004303-index.htm
2020-02-10Nicole D PerryVice President - FinanceBuy2,500.002,500.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004275/0000899243-20-004275-index.htm
2020-02-10Ahmad SadrOfficerBuy2,725.002,725.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004264/0000899243-20-004264-index.htm
2020-11-02Federico GrossiCHIEF MEDICAL OFFICERSell600.0031.0918,654.0027,725.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220027991/0001127602-20-027991-index.htm
2020-10-01Federico GrossiOfficerSell600.0030.2218,132.0028,325.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220026264/0001127602-20-026264-index.htm
2020-09-01Federico GrossiOfficerSell600.0031.5818,948.0028,925.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220024640/0001127602-20-024640-index.htm
2020-08-03Federico GrossiOfficerSell600.0026.2815,768.0029,525.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220022885/0001127602-20-022885-index.htm
2020-07-01Federico GrossiOfficerSell850.0032.4327,565.5030,125.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220021048/0001127602-20-021048-index.htm
2020-06-15Federico GrossiOfficerSell856.0030.2125,859.7630,975.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220019735/0001127602-20-019735-index.htm
2020-02-10Federico GrossiOfficerBuy9,375.0031,831.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004262/0000899243-20-004262-index.htm
2020-02-10David O. WatsonGeneral CounselSell5,000.0044.50222,500.0035,417.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004260/0000899243-20-004260-index.htm
2020-10-07Victoria L. BrownProgram Team LeadSell12,000.0035.00420,000.003,607.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220026748/0001127602-20-026748-index.htm
2020-02-10David O. WatsonGeneral CounselBuy6,375.0040,417.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004260/0000899243-20-004260-index.htm
2020-02-10David O. WatsonGeneral CounselBuy7,505.002.6720,038.3542,922.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004260/0000899243-20-004260-index.htm
2020-05-08PAUL R. FONTEYNEDirectorBuy5,000.0031.81159,034.005,000.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220016304/0001127602-20-016304-index.htm
2020-02-10Lucia CelonaOfficerBuy5,213.005,213.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004281/0000899243-20-004281-index.htm
2020-02-14Alec MachielsDirectorSell2,500.0042.35105,875.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006429/0001127602-20-006429-index.htm
2020-03-25Alec MachielsDirectorSell2,500.0030.0075,000.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011988/0001127602-20-011988-index.htm
2020-04-15Alec MachielsDirectorSell2,500.0030.0075,000.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220014098/0001127602-20-014098-index.htm
2020-05-15Alec MachielsDirectorSell2,500.0030.0075,000.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220017178/0001127602-20-017178-index.htm
2020-06-15Alec MachielsDirectorSell2,500.0030.2175,525.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220019733/0001127602-20-019733-index.htm
2020-10-07Alec MachielsDirectorSell7,500.0035.00262,500.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220026750/0001127602-20-026750-index.htm
2020-10-15Alec MachielsDirectorSell2,500.0035.0087,500.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220027101/0001127602-20-027101-index.htm
2020-02-14Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006429/0001127602-20-006429-index.htm
2020-03-25Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011988/0001127602-20-011988-index.htm
2020-04-15Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220014098/0001127602-20-014098-index.htm
2020-05-15Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220017178/0001127602-20-017178-index.htm
2020-06-15Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220019733/0001127602-20-019733-index.htm
2020-10-15Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220027101/0001127602-20-027101-index.htm
2020-10-07Alec MachielsDirectorBuy7,500.002.6720,025.00677,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220026750/0001127602-20-026750-index.htm
2020-02-10Thomas A. LacknerOfficerBuy2,725.007,725.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004268/0000899243-20-004268-index.htm
2020-02-10Pascal DeschateletsChief Operating OfficerBuy9,375.00891,118.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004312/0000899243-20-004312-index.htm
2020-02-10Adam J. TownsendOfficerBuy9,375.009,375.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004288/0000899243-20-004288-index.htm
2020-02-12Pascal DeschateletsChief Operating OfficerSell52,075.0042.802,228,966.23946,874.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220005685/0001127602-20-005685-index.htm
2020-02-12Pascal DeschateletsChief Operating OfficerBuy117,206.002.14250,820.84998,949.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220005685/0001127602-20-005685-index.htm